Activation and Regulation of Hemostasis in Acute Liver Failure and Acute Pancreatitis

ABSTRACT

Acute liver failure and acute pancreatitis are accompanied by substantial changes in the hemostatic system. In acute liver failure, defective synthesis of coagulation factors and intravascular activation of coagulation results in thrombocytopenia and reduced levels of proteins involved in coagulation and fibrinolysis. Acute pancreatitis may be accompanied by intravascular activation of hemostasis mediated by inflammation and exposure of pancreatic tissue factor to the bloodstream. In animal models for both diseases, activation of hemostasis appears to contribute to the progression of the disease. Consequently, the use of anticoagulants may, in theory, be beneficial in humans. In practice, however, clinical use of anticoagulants in these patients is likely hampered by a substantial bleeding risk.

KEYWORDS

Liver - platelet - coagulation - hemostasis - fibrin - pancreatitis

REFERENCES

• 1 Lisman T, Leebeek F W. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment.  Dig Surg. 2007;  24(4) 250-258
• 2 Tripodi A, Salerno F, Chantarangkul V et al.. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.  Hepatology. 2005;  41(3) 553-558
• 3 Lisman T, Bongers T N, Adelmeijer J et al.. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity.  Hepatology. 2006;  44(1) 53-61
• 4 de Boer M T, Molenaar I Q, Hendriks H G, Slooff M J, Porte R J. Minimizing blood loss in liver transplantation: progress through research and evolution of techniques.  Dig Surg. 2005;  22(4) 265-275
• 5 Warnaar N, Lisman T, Porte R J. The two tales of coagulation in liver transplantation.  Curr Opin Organ Transplant. 2008;  13(3) 298-303
• 6 Caldwell S H, Hoffman M, Lisman T Coagulation in Liver Disease Group et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.  Hepatology. 2006;  44(4) 1039-1046
• 7 Kakafika A, Papadopoulos V, Mimidis K, Mikhailidis D P. Coagulation, platelets, and acute pancreatitis.  Pancreas. 2007;  34(1) 15-20
• 8 Maeda K, Hirota M, Ichihara A et al.. Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis.  Pancreas. 2006;  32(1) 87-92
• 9 Stravitz R T, Kramer A H, Davern T Acute Liver Failure Study Group et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group.  Crit Care Med. 2007;  35(11) 2498-2508
• 10 Munoz S J, Stravitz R T, Gabriel D A. Coagulopathy of acute liver failure.  Clin Liver Dis. 2009;  13(1) 95-107
• 11 Anand A C, Nightingale P, Neuberger J M. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria.  J Hepatol. 1997;  26(1) 62-68
• 12 Munoz S J, Rajender Reddy K, Lee W. Acute Liver Failure Study Group . The coagulopathy of acute liver failure and implications for intracranial pressure monitoring.  Neurocrit Care. 2008;  9(1) 103-107
• 13 Pernambuco J R, Langley P G, Hughes R D, Izumi S, Williams R. Activation of the fibrinolytic system in patients with fulminant liver failure.  Hepatology. 1993;  18(6) 1350-1356
• 14 Kerr R, Newsome P, Germain L et al.. Effects of acute liver injury on blood coagulation.  J Thromb Haemost. 2003;  1(4) 754-759
• 15 Lisman T, Leebeek F W, Mosnier L O et al.. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.  Gastroenterology. 2001;  121(1) 131-139
• 16 Colucci M, Binetti B M, Branca M G et al.. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.  Hepatology. 2003;  38(1) 230-237
• 17 Cornillon B, Paul J, Belleville J, Aurousseau A M, Clendinnen G, Eloy R. Experimental DMNA induced hepatic necrosis: early course of haemostatic disorders in the rat.  Comp Biochem Physiol C. 1985;  80(2) 277-284
• 18 Hollestelle M J, Poyck P P, Hollestelle J M, Marsman H A, Mourik J A, Gulik T M. Extra-hepatic factor VIII expression in porcine fulminant hepatic failure.  J Thromb Haemost. 2005;  3(10) 2274-2280
• 19 Schiødt F V, Balko J, Schilsky M, Harrison M E, Thornton A, Lee W M. Acute Liver Failure Study Group . Thrombopoietin in acute liver failure.  Hepatology. 2003;  37(3) 558-561
• 20 Goulis J, Chau T N, Jordan S et al.. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation.  Gut. 1999;  44(5) 754-758
• 21 Ganey P E, Luyendyk J P, Newport S W et al.. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice.  Hepatology. 2007;  46(4) 1177-1186
• 22 Kume M, Hayashi T, Yuasa H et al.. Bacterial lipopolysaccharide decreases thrombomodulin expression in the sinusoidal endothelial cells of rats—a possible mechanism of intrasinusoidal microthrombus formation and liver dysfunction.  J Hepatol. 2003;  38(1) 9-17
• 23 Hillenbrand P, Parbhoo S P, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure.  Gut. 1974;  15(2) 83-88
• 24 Hughes R D, Lane D A, Ireland H, Langley P G, Gimson A E, Williams R. Fibrinogen derivatives and platelet activation products in acute and chronic liver disease.  Clin Sci (Lond). 1985;  68(6) 701-707
• 25 Langley P G, Forbes A, Hughes R D, Williams R. Thrombin-antithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome.  Eur J Clin Invest. 1990;  20(6) 627-631
• 26 Langley P G, Williams R. The effect of fulminant hepatic failure on protein C antigen and activity.  Thromb Haemost. 1988;  59(2) 316-318
• 27 Tripodi A, Mannucci P M. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research.  J Hepatol. 2007;  46(4) 727-733
• 28 Lisman T, Caldwell S H, Leebeek F WG, Porte R J. Is chronic liver disease associated with a bleeding diathesis?.  J Thromb Haemost. 2006;  4(9) 2059-2060
• 29 Mannucci P M. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No.  J Thromb Haemost. 2006;  4(4) 721-723
• 30 Northup P G, Sundaram V, Fallon M B Coagulation in Liver Disease Group et al. Hypercoagulation and thrombophilia in liver disease.  J Thromb Haemost. 2008;  6(1) 2-9
• 31 Massicotte L, Beaulieu D, Thibeault L et al.. Coagulation defects do not predict blood product requirements during liver transplantation.  Transplantation. 2008;  85(7) 956-962
• 32 Gazzard B G, Henderson J M, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy.  Gut. 1975;  16(8) 617-620
• 33 Fujiwara K, Ogata I, Ohta Y et al.. Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III.  Gut. 1988;  29(8) 1103-1108
• 34 Gazzard B G, Clark R, Borirakchanyavat V, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis.  Gut. 1974;  15(2) 89-93
• 35 Anstee Q M, Goldin R D, Wright M, Martinelli A, Cox R, Thursz M R. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies.  J Thromb Haemost. 2008;  6(8) 1336-1343
• 36 Wright M, Goldin R, Hellier S et al.. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection.  Gut. 2003;  52(8) 1206-1210
• 37 Bhatia M, Wong F L, Cao Y et al.. Pathophysiology of acute pancreatitis.  Pancreatology. 2005;  5(2–3) 132-144
• 38 Bhatia M. Inflammatory response on the pancreatic acinar cell injury.  Scand J Surg. 2005;  94(2) 97-102
• 39 Levi M, ten Cate H, van der Poll T, van Deventer S J. Pathogenesis of disseminated intravascular coagulation in sepsis.  JAMA. 1993;  270(8) 975-979
• 40 Bockman D E, Büchler M, Beger H G. Ultrastructure of human acute pancreatitis.  Int J Pancreatol. 1986;  1(2) 141-153
• 41 Moberg L, Johansson H, Lukinius A et al.. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation.  Lancet. 2002;  360(9350) 2039-2045
• 42 Radenkovic D, Bajec D, Ivancevic N et al.. D-dimer in acute pancreatitis: a new approach for an early assessment of organ failure.  Pancreas. 2009;  38(6) 655-660
• 43 Hackert T, Werner J, Gebhard M M, Klar E. Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitis.  Surgery. 2004;  135(2) 131-138
• 44 Hagiwara S, Iwasaka H, Shingu C, Matsumoto S, Uchida T, Noguchi T. Antithrombin III prevents cerulein-induced acute pancreatitis in rats.  Pancreas. 2009;  38(7) 746-751
• 45 Hackert T, Sperber R, Hartwig W et al.. P-selectin inhibition reduces severity of acute experimental pancreatitis.  Pancreatology. 2009;  9(4) 369-374
• 46 Andersson E, Axelsson J, Pedersen L C, Elm T, Andersson R. Treatment with anti-factor VIIa in acute pancreatitis in rats: blocking both coagulation and inflammation?.  Scand J Gastroenterol. 2007;  42(6) 765-770
• 47 Ping C, Yongping Z, Minmin Q, Weiyan Y, Yaozong Y. Activated protein C improves the severity of severe acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin.  Dig Dis Sci. 2009;  , August 13 (Epub ahead of print)
• 48 Alsfasser G, Warshaw A L, Thayer S P et al.. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis.  Arch Surg. 2006;  141(7) 670-676 discussion 676-677
• 49 Jamdar S, Siriwardena A K. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.  Crit Care. 2005;  9(4) 321-322
• 50 Kerschen E J, Fernandez J A, Cooley B C et al.. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.  J Exp Med. 2007;  204(10) 2439-2448